Literature DB >> 32301842

Morbidity and Mortality in Critically Ill Children. I. Pathophysiologies and Potential Therapeutic Solutions.

Murray M Pollack1, Russell Banks2, Richard Holubkov2, Kathleen L Meert3.   

Abstract

OBJECTIVES: Developing effective therapies to reduce morbidity and mortality requires knowing the responsible pathophysiologies and the therapeutic advances that are likely to be impactful. Our objective was to determine at the individual patient level the important pathophysiological processes and needed therapeutic additions and advances that could prevent or ameliorate morbidities and mortalities.
DESIGN: Structured chart review by pediatric intensivists of PICU children discharged with significant new morbidity or mortality to determine the pathophysiologies responsible for poor outcomes and needed therapeutic advances.
SETTING: Multicenter study (eight sites) from the Collaborative Pediatric Critical Care Research Network of general and cardiac PICUs. PATIENTS: First PICU admission of patients from December 2011 to April 2013.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Two-hundred ninety-two patients were randomly selected from 681 patients discharged with significant new morbidity or mortality. The median age was 2.4 years, 233 (79.8%) were in medical/surgical ICUs, 59 (20.2%) were in cardiac ICUs. Sixty-five (22.3%) were surgical admissions. The outcomes included 117 deaths and 175 significant new morbidities. The most common pathophysiologies contributing to the poor outcomes were impaired substrate delivery (n = 158, 54.1%) and inflammation (n = 104, 35.6%). There were no strong correlations between the pathophysiologies and no remarkable clusters among them. The most common therapeutic needs involved new drugs (n = 149, 51.0%), cell regeneration (n = 115, 39.4%), and immune and inflammatory modulation (n = 79, 27.1%). As with the pathophysiologies, there was a lack of strong correlations or meaningful clusters in the suggested therapeutic needs.
CONCLUSIONS: There was no single dominant pathophysiology or cluster of pathophysiologies responsible for poor pediatric critical care outcomes. Therapeutic needs often involved therapies that are not close to implementation such as cell regeneration, improved organ transplant, improved extracorporeal support and artificial organs, and improved drugs.

Entities:  

Mesh:

Year:  2020        PMID: 32301842      PMCID: PMC7242139          DOI: 10.1097/CCM.0000000000004331

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  38 in total

1.  Research agenda. Opportunities for research and NIH.

Authors:  Francis S Collins
Journal:  Science       Date:  2010-01-01       Impact factor: 47.728

2.  Prioritizing a research agenda: a Delphi study of the better outcomes through research for newborns (BORN) network.

Authors:  Elizabeth Simpson; Neera K Goyal; Niramol Dhepyasuwan; Valerie J Flaherman; Esther K Chung; Isabelle Von Kohorn; Anthony Burgos; James Taylor
Journal:  Hosp Pediatr       Date:  2014-07

Review 3.  The intensive care medicine clinical research agenda in paediatrics.

Authors:  Mark J Peters; Andrew Argent; Marino Festa; Stéphane Leteurtre; Jefferson Piva; Ann Thompson; Douglas Willson; Pierre Tissières; Marisa Tucci; Jacques Lacroix
Journal:  Intensive Care Med       Date:  2017-03-17       Impact factor: 17.440

4.  A study of medical injury and medical malpractice.

Authors:  H H Hiatt; B A Barnes; T A Brennan; N M Laird; A G Lawthers; L L Leape; A R Localio; J P Newhouse; L M Peterson; K E Thorpe
Journal:  N Engl J Med       Date:  1989-08-17       Impact factor: 91.245

Review 5.  Reducing the burden of surgical harm: a systematic review of the interventions used to reduce adverse events in surgery.

Authors:  Ann-Marie Howell; Sukhmeet S Panesar; Elaine M Burns; Liam J Donaldson; Ara Darzi
Journal:  Ann Surg       Date:  2014-04       Impact factor: 12.969

Review 6.  Cell therapy approaches for lung diseases: current status.

Authors:  Viranuj Sueblinvong; Daniel J Weiss
Journal:  Curr Opin Pharmacol       Date:  2009-04-06       Impact factor: 5.547

7.  Functional Status Scale: new pediatric outcome measure.

Authors:  Murray M Pollack; Richard Holubkov; Penny Glass; J Michael Dean; Kathleen L Meert; Jerry Zimmerman; Kanwaljeet J S Anand; Joseph Carcillo; Christopher J L Newth; Rick Harrison; Douglas F Willson; Carol Nicholson
Journal:  Pediatrics       Date:  2009-07       Impact factor: 7.124

Review 8.  Lung Regeneration Therapy for Chronic Obstructive Pulmonary Disease.

Authors:  Dong Kyu Oh; You-Sun Kim; Yeon-Mok Oh
Journal:  Tuberc Respir Dis (Seoul)       Date:  2016-12-30

Review 9.  Precision medicine for all? Challenges and opportunities for a precision medicine approach to critical illness.

Authors:  Christopher W Seymour; Hernando Gomez; Chung-Chou H Chang; Gilles Clermont; John A Kellum; Jason Kennedy; Sachin Yende; Derek C Angus
Journal:  Crit Care       Date:  2017-10-18       Impact factor: 9.097

10.  The Pediatric Risk of Mortality Score: Update 2015.

Authors:  Murray M Pollack; Richard Holubkov; Tomohiko Funai; J Michael Dean; John T Berger; David L Wessel; Kathleen Meert; Robert A Berg; Christopher J L Newth; Rick E Harrison; Joseph Carcillo; Heidi Dalton; Thomas Shanley; Tammara L Jenkins; Robert Tamburro
Journal:  Pediatr Crit Care Med       Date:  2016-01       Impact factor: 3.624

View more
  3 in total

1.  Association of Socioeconomic Status With Postdischarge Pediatric Resource Use and Quality of Life.

Authors:  Alicia G Kachmar; R Scott Watson; David Wypij; Mallory A Perry; Martha A Q Curley
Journal:  Crit Care Med       Date:  2022-02-01       Impact factor: 9.296

2.  Functional outcomes at PICU discharge in hemato-oncology children at a tertiary oncology center in Hong Kong.

Authors:  Karen K Y Leung; Samiran Ray; Godfrey C F Chan; Kam Lun Hon
Journal:  Int J Clin Oncol       Date:  2022-09-23       Impact factor: 3.850

3.  Morbidity and Mortality in Critically Ill Children. II. A Qualitative Patient-Level Analysis of Pathophysiologies and Potential Therapeutic Solutions.

Authors:  Kathleen L Meert; Russell Banks; Richard Holubkov; Murray M Pollack
Journal:  Crit Care Med       Date:  2020-06       Impact factor: 7.598

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.